Analyst Price Targets — SRZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 11:13 am | — | Cantor Fitzgerald | $40.00 | $25.09 | TheFly | Surrozen initiated with an Overweight at Cantor Fitzgerald |
| January 30, 2025 11:04 am | Matthew Caufield | H.C. Wainwright | $32.00 | $11.25 | TheFly | Surrozen initiated with a Buy at H.C. Wainwright |
| January 3, 2025 11:15 am | Yatin Suneja | Guggenheim | $45.00 | $17.45 | TheFly | Surrozen upgraded to Buy from Neutral at Guggenheim |
Latest News for SRZN
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of…
Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRZN.
U.S. House Trading
No House trades found for SRZN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.